Androgen eye ointment for treatment of dry eyes in post menopausal women

Effectiveness of administering low-dose ocular androgen for post-menopausal dry eye - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/088458

Enrollment

Registered

2025-06-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H579- Unspecified disorder of eye and adnexa

Interventions

Intervention1: Androgen ophthalmic preparation: 0.03% androgen eye ointment. Control Intervention1: Placebo: 1% Carboxymethylcellulose Lubricating eye gel

Eligibility

Inclusion criteria

Inclusion criteria: Women reporting natural menopause (1 year amenorrhea) aged 50-60 years diagnosed with dry eye, who are willing to consent for participating in the study and adhere to study protocol.

Exclusion criteria

Exclusion criteria: Patients with presence of other significant ocular surface pathologies (e.g., conjunctivitis, keratitis, Glaucoma); Any androgen-linked disorders or contraindications for androgen therapy; Use of systemic or topical medications affecting ocular surface health; Current or recent use of other dry eye treatments; Unwilling subjects will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Schirmer Test Results, Tear Break-up time, Ocular Surface Disease IndexTimepoint: Baseline, weekly follow ups till 3 weeks, bi weekly follow ups till another one month	—

Secondary

Measure	Time frame
Dry Eye Related Quality of Life ScoreTimepoint: Baseline and after 7 weeks	—

Countries

India

Contacts

Public ContactHarshita Pandey

Galgotias University

harsh21997@gmail.com8126653610

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026